Credit Suisse analyst Martin Auster downgraded AnaptysBio to Neutral from Outperform and lowered his price target to $79 from $137 after the company said the principal investigator of the etokimab atopic dermatitis Phase 2a trial stated that topical corticosteroids were utilized as a rescue therapy in the study in controlled amounts, among a "small" number of patients," and that use was "immaterial" and "on a limited basis." Auster also notes that management says the use of rescue medications is "unlikely" to have impacted the efficacy as reported, but reduced his assumed probability of success for etokimab in AD to 35% from 55% and in asthma to 40% from 45%.